Stockscreener 앱 받기
4.055
3.69%
0.125
전일 마감가:
$3.93
열려 있는:
$3.91
하루 거래량:
766.44K
Relative Volume:
0.88
시가총액:
$523.67M
수익:
$204.17M
순이익/손실:
$-74.00M
주가수익비율:
-7.0216
EPS:
-0.5775
순현금흐름:
$-12.84M
1주 성능:
-1.33%
1개월 성능:
+19.68%
6개월 성능:
-13.30%
1년 성능:
+23.48%
1일 변동 폭
$3.83
$4.095
1주일 범위
$3.83
$4.195
52주 변동 폭
$2.90
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
명칭
Cytek Biosciences Inc
전화
(877) 922-9835
주소
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.055 | 507.53M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
89.76 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
309.29 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.19 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.73 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.33 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-09 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-31 | 다운그레이드 | Goldman | Buy → Sell |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-07-19 | 개시 | Raymond James | Mkt Perform |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
모두보기
Cytek Biosciences Inc 주식(CTKB)의 최신 뉴스
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary - Quartr
Cytek Biosciences (CTKB) director converts 43,973 RSUs to common stock - Stock Titan
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report - Stock Titan
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs - Stock Titan
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants - Stock Titan
Cytek Biosciences (CTKB) director exercises RSUs and receives new equity awards - Stock Titan
Cytek Biosciences (CTKB) director exercises 43,973 RSUs, granted options and RSUs - Stock Titan
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference - GlobeNewswire
Cytek Biosciences debuts Borealis spectral cytometer - SelectScience
Cytek Biosciences Shares Fall After Borealis News and Sales Exit - Bez Kabli
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 - BioSpace
Cytek Biosciences Announces Resignation of Senior Sales Executive - TipRanks
Cytek Biosciences' Philippe Busque resigns as Senior VP, Global Sales and Services - TradingView
Cytek Biosciences, Inc. Announces Resignation of Philippe Busque from Senior Vice President, Global Sales and Services, Effective June 5, 2026 - marketscreener.com
Cytek Biosciences (CTKB) SVP Global Sales and Services to step down June 5, 2026 - Stock Titan
Cytek Biosciences explores new vaccine strategies targeting mucosal immunity - Traders Union
Promising Penny Stocks To Consider In June 2026 - simplywall.st
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Cytek Biosciences launches on-demand webinar on hMSC variation impacting regenerative medicine - Traders Union
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming - Moomoo
Cytek Biosciences schedules webinar to advance deep immunophenotyping techniques - Traders Union
Cytek Biosciences (CTKB) Edges Higher as Support Holds, Resistance in FocusRSI Overbought Alerts - The Legal Advocate
Cytek Biosciences Q1 2026 Earnings: Deep EPS Miss Fails to Dampen Investor SentimentPre-Announcement Alert - Newser
Cytek Biosciences Reaches US$487m Market Cap Benefiting Insider Stock Buying - 富途牛牛
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares - Stock Titan
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding - Stock Titan
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding - Stock Titan
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes - Stock Titan
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting - Stock Titan
Cytek (CTKB) Q1 2026 Disappoints — EPS $-0.15 Below $-0.10 ViewsCommunity Watchlist Picks - Newser
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI - Traders Union
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026) - Stock Titan
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth - Investing.com
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com - Investing.com Nigeria
Stephens cuts Cytek Biosciences stock price target on elevated costs - Investing.com UK
TradingKey - TradingKey
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating - marketscreener.com
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
The strategic moves Cytek (CTKB) is making now (Investor Concern) 2026-05-11Dividend Growth - newser.com
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Cytek Biosciences Inc (CTKB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
0.28%
자본화:
|
볼륨(24시간):